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Effectiveness and safety of vedolizumab for treatment of 
Crohn’s disease: a systematic review and meta-analysis
Paweł Moćko1, Paweł Kawalec1, Beata Smela-Lipińska1, Andrzej Pilc2
A b s t r a c t 
Introduction: The aim of this systematic review (SR) and meta-analysis was 
to assess the efficacy and safety of vedolizumab in the treatment of Crohn’s 
disease (CD).
Material and methods: A systematic literature search was conducted in 
Medline/PubMed, Embase and Cochrane Library until 25 January, 2015. In-
cluded studies were critically appraised according to the PRISMA protocol. 
Assessment in specified subgroups of CD patients and meta-analysis with 
Revman software were performed. 
Results: Two randomized controlled trial (RCTs) were included in a me-
ta-analysis for the induction phase of therapy: GEMINI II and GEMINI III. The 
clinical response was significantly higher for patients who received vedol-
izumab compared to placebo in the general population (risk benefit (RB) = 
1.48; p = 0.0006) and in both analyzed subgroups: patients with previous 
failure of anti-TNFs treatment (RB = 1.51; p = 0.006) and patients naive to 
earlier anti-TNFs (RB = 1.41; p = 0.001). The clinical remission in the general 
population and subpopulation of TNF-antagonist naive patients was signifi-
cantly higher for patients who received vedolizumab compared to placebo 
(RB = 1.77; p = 0.003; RB = 2.29; p = 0.0004; respectively). Meta-analysis 
for adverse events, serious adverse events (SAEs) and serious infections, 
revealed that vedolizumab was as safe as placebo in the induction phase 
of therapy. 
Conclusions: The clinical response was significantly higher for patients 
who received vedolizumab in the general population and in both analyzed 
subgroups of patients. The clinical remission in the general population and 
subpopulation of TNF-antagonist naive patients was significantly higher for 
vedolizumab, but no significant differences were revealed in the subgroup of 
patients with previous TNF antagonist failure.
Key words: Crohn’s disease, vedolizumab, MLN-002, meta-analysis, 
systematic review.
Introduction
Crohn’s disease (CD) is one of two main forms of inflammatory 
bowel disease (IBD) (the second one is ulcerative colitis) [1, 2]. The 
primary difference between the two forms of IBD is the location and 
nature of the inflammatory changes. Crohn’s disease is characterized 
by the fact that it may affect any part of the gastrointestinal tract 
from mouth to anus, but most frequently involves the distal small in-
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testine and proximal colon [1]. Crohn’s disease 
is a  relapsing systemic inflammatory disease 
with complications such as strictures, abscess-
es, sinus tracts and fistulae. Crohn’s disease can 
result in a  wide variety of symptoms including 
abdominal pain, diarrhea and weight loss; there 
also occur pain and fever, which can signify de-
velopment of an abscess. Choice of the initial 
drug for CD depends on phenotype, comorbid-
ities, disease activity, and other individual char-
acteristics of a patient. In most cases, fast-act-
ing, short-term use agents (such as steroids or 
anti-tumor necrosis factor (TNF)) are combined 
with thiopurines or methotrexate. The choice of 
treatment should consider efficacy, side-effects 
and long-term complications [2].
Vedolizumab is a humanized monoclonal IgG1 
antibody which inhibits migration and adhesion 
of leukocytes (by deactivation of α4β7 integ-
rin) into the gastrointestinal tract. Its activity is 
focused on α4β7 MAdCAM-1 binding, which is 
expressed mostly in the gastrointestinal tract, 
so use of vedolizumab could provide advantages 
compared with use of anti-α4 antibodies (e.g. na-
talizumab) due to lower risk of drug-related side 
effects [3–6]. 
The aim of the systematic review and meta-anal-
ysis was to examine the efficacy and safety of 
vedolizumab for the treatment of CD compared to 
placebo; additional analyses were performed for use 
of the drug in specified subgroups of CD patients. 
Material and methods
Literature search strategy
The search strategy was based on the med-
ical subject heading MeSH terms and EMTREE 
combined with Boole’s logical operators (Table I). 
The systematic literature review was conducted 
using the following main electronic databases: 
Medline via PubMed, Embase and the Cochrane 
Central Register of Controlled Trials (CENTRAL), 
until 25.01.2015. Additional relevant studies 
were identified by searching the Cochrane IBD/
FBD Review Group Specialized Trials Register, as 
well as websites of the British Society of Gastro-
enterology (BSG) and the European Crohn’s and 
Colitis Organization (ECCO). The Cochrane Data-
base of Systematic Reviews (CDSR), and Med-
line via PubMed and Embase databases were 
also searched for review articles. The reference 
lists of included studies and review articles were 
screened to identify additional eligible studies. 
Randomized controlled trials (RCTs) compar-
ing vedolizumab with placebo in patients with 
Crohn’s disease were included. 
Selection criteria
Studies were identified using the search strat-
egy by two independent reviewers (P.M. and 
B.SL.). When there was uncertainty regarding 
eligibility, a  third reviewer was consulted (P.K.). 
Study selection was based on the title and ab-
stract and, if necessary, full-text articles. Refer-
ences of identified studies were hand searched 
for other relevant studies. All eligible RCTs were 
critically appraised and analyzed according to 
the PRISMA Statement protocol [7]. Studies were 
selected for inclusion in this analysis based on 
the following criteria: 1) randomized control tri-
al (RTC); 2) patients treated for CD; 3) the inter-
vention assessed was vedolizumab. Results from 
non-randomized or uncontrolled or open-label 
studies were not incorporated into the dataset. 
Full-text articles were included if they contained 
required information about study population, 
treatment regimen and necessary data to ex-
tract. However, non-published studies were also 
taken into consideration. Abstracts or posters 
after screening were excluded. Non-English pub-
lications were excluded.
Data extraction
Data was also extracted independently by two 
reviewers (P.M. and P.K.) using pre-defined data 
extraction forms. The following data were extract-
ed from studies that met the inclusion criteria: 
Table I. MeSH subject headings and EMTREE keywords used in constructed search strategy for the primary studies
Key words (combined with Boole’s Logical Operator, AND/OR)
Medical condition (Crohn disease OR Crohn’s Disease OR Crohns Disease OR Crohn’s Enteritis OR Regional 
Enteritis OR Enteritis Regionalis OR Regional Enterocolitis OR Intestinal tract, Regional 
enteritis OR Inflammatory Bowel Disease 1 OR Granulomatous Enteritis OR Ileocolitis 
OR Granulomatous Colitis OR Terminal Ileitis OR Regional Ileitides OR Regional Ileitis OR 
Cleron disease OR Morbus Crohn)
Intervention (Vedolizumab OR mln0002 OR mln 0002 OR mln 02 OR mln02 OR monoclonal antibody 
mln 02 OR monoclonal antibody ldp 02 OR ldp 02, ldp02 OR entyvio)
Methodological limits PubMed: humans; EMBASE: humans, Embase only; Cochrane: Cochrane Central Register of 
Controlled Trials: No limits applied, word variations have been searched
Language limits Only English publications
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characteristics of participants, intervention and 
regimen details, clinical endpoints, follow-up pe-
riod, and study design. For the efficacy analysis, 
data on clinical response and clinical remission 
were extracted. The safety analysis included the 
following data: any adverse events (AEs), any seri-
ous adverse events (SAEs) and serious infections. 
The  methodological quality of eligible RCTs was 
assessed using the Collaboration’s recommend-
ed tool for assessing risk of bias – domain-based 
evaluation. In assessing the risk of bias, “+” is 
granted in the case of low risk of bias, “–” indi-
cates a high risk of bias, while “?” indicates un-
clear risk of bias [8]. 
Statistical analysis
Data were analyzed using intention-to-treat 
(ITT) results from the included studies. The influ-
ence of intervention was expressed as a relative 
benefit (RB; described as risk ratio in the graphs 
presented due to specific labeling of effect mea-
surement in the statistical analysis software) to 
the positive outcomes (clinical response, clinical 
remission) or a  relative risk (RR) to the nega-
tive outcomes (the other analyzed endpoints), 
respectively. Meta-analysis was performed only 
for homogeneous data determined by degree 
of clinical and statistical heterogeneity. Clini-
cal heterogeneity was assessed on the basis of 
characteristics of the included studies, whereas 
the statistical heterogeneity of the trial results 
was evaluated using the c2 test and the I2 test. 
Heterogeneity of study results was considered 
statistically significant at p < 0.1, and then the 
random-effects model was used, while at p ≥ 0.1 
the fixed-effects model was applied. The analy-
sis used a  conservative approach, in which the 
value of the c2 test (p-value) below the thresh-
old of 0.1 (the value of the low sensitivity of the 
test) indicates that differences are not acciden-
tal. Additionally the rated parameter I2 evaluates 
heterogeneity of results. A  value in the range 
0–40% indicates likely insignificant heterogene-
ity, 30–60% moderate heterogeneity, 50–90% is 
high inhomogeneity, and heterogeneity is 75–
100%, which allows the pooled analysis of the 
data only if being particularly critical in the in-
terpretation of results [9]. For other calculations 
statistical significance was defined at p < 0.05. 
We performed a  meta-analysis and all statisti-
cal tests and created forest plots using Review 
Manager 5.3 software. The graphic presentation 
of meta-analyses applied a  forest plot in which 
the squares marked results of individual studies 
with the horizontal lines representing confidence 
intervals and a rhombus indicating the results of 
all studies pooled (meta-analysis).
Results 
Literature search – description and quality 
of included studies
The search results of RCTs are summarized in 
Figure 1. A total of 497 potentially relevant studies 
were identified in the literature search; 43 of them 
were duplicates, and the other 438 studies were 
excluded after the screening of titles and abstracts.
Thus, 16 full-text articles were reviewed, of 
which 13 were excluded and a  total of 3 RCTs 
[10–12] were considered in the meta-analysis. 
Two of these three studies [10, 11] did not differ 
significantly in terms of population characteris-
tics; the definitions of chosen endpoints – clini-
cal response and clinical remission – were exactly 
the same and other methods were similar – these 
two studies were homogeneous enough to be me-
ta-analyzed. Table II summarizes characteristic of 
trials included in the qualitative synthesis in the 
present study. The methodological quality of the 
meta-analyzed RCTs was evaluated as high. The 
probability of occurrence of bias in most studies 
and domains was considered low (Figure 2). Both 
trials were randomized and double blinded. They 
also provided data relating to the number of pa-
tient withdrawals. 
Clinical remission
Clinical remission was defined in both reference 
studies as a Crohn’s Disease Activity Index (CDAI) 
score of ≤ 150 points. There was no evidence of Figure 1. Search flow diagram
497 of records identified through database 
searching (PubMed = 38, Embase = 443, 
Cochrane = 16)
43 of records after duplicates removed
454 of records screened
16 of full-text articles 
assessed for eligibility
3 of studies included in 
qualitative synthesis
2 of studies included in 
quantitative synthesis 
(meta-analysis)
438 of records excluded 
after titles and abstract 
screening
14 of full-text articles 
excluded, with reasons:
– duplicate (2)
– review (8)
– abstract (2)
– others (2)
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significant heterogeneity when data from the 
studies were pooled; therefore, a fixed-effect mod-
el was used for the analysis of clinical remission. 
The meta-analysis revealed that clinical remission 
was significantly higher for patients who received 
vedolizumab as compared to control patients 
(Figure 3 A). Subgroup analysis for the pooled 
clinical remission rates was performed according 
to the earlier response of patients to TNF antag-
onist treatment. The subpopulation of patients 
who previously reported no response and/or poor 
tolerance of the treatment with TNF antagonists 
was also analyzed; the results of the meta-analy-
sis showed no statistically significant differences 
in clinical remission between groups treated with 
vedolizumab or placebo (Figure 3 B). The meta- 
analysis in the subpopulation of patients naive 
to earlier TNF antagonist treatment revealed that 
clinical remission was significantly higher for pa-
tients who received vedolizumab as compared to 
control patients (Figure 3 C).
Clinical response rate
Clinical response was defined as a ≥ 100-point 
decrease in the CDAI score from output values in 
both analyzed studies. In the general population 
the clinical response to vedolizumab was higher 
than in the placebo groups (Figure 4). The fixed-ef-
fect model was used for analysis of the clinical re-
sponse because there was no evidence of signif-
icant heterogeneity when data from the studies 
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Figure 2. Risk of bias summary
Sands et al. 
2014 [11]
Feagan et al. 
2008 [12]
Sandborn et al. 
2013 [10]
Figure 3. Forest plot of meta-analysis for vedolizumab vs. placebo of clinical remission: A – in the general popula-
tion (ITT analysis) at week 6, B – in the subpopulation of patients who reported no response and/or poor tolerance 
of the prior treatment with TNF antagonists at week 6, and C – in the TNF antagonist-naive subgroup at week 6
A
General population (ITT analysis)
Study or subgroup     Vedolizumab         Placebo Weight (%) Risk ratio Risk ratio
 Events Total Events Total  MH, fixed, 95% CI MH, fixed, 95% CI
Sandborn et al. 2013 32 220 10 148 32.2 2.15 (1.09–4.24)
Sands et al. 2014 40 209 25 207 67.8 1.58 (1.00–2.51)
Total (95% CI)  429  355 100.0 1.77 (1.21–2.59)
Total events 72  35
Heterogeneity: c2 = 0.54, df = 1 (p = 0.46); I2 = 0%
Test for overall effect: Z = 2.92 (p = 0.003)
B
Subpopulation of patients who reported no response and/or poor tolerance of the prior treatment with TNF anatagonists
Study or subgroup     Vedolizumab         Placebo Weight (%) Risk ratio Risk ratio
 Events Total Events Total  MH, fixed, 95% CI MH, fixed, 95% CI
Sandborn et al. 2013 11 105 3 70 15.9 2.44 (0.71–8.45)
Sands et al. 2014 24 158 19 157 84.1 1.26 (0.72–2.20)
Total (95% CI)  263  227 100.0 1.44 (0.87–2.40)
Total events 35  22
Heterogeneity: c2 = 0.93, df = 1 (p = 0.33); I2 = 0%
Test for overall effect: Z = 1.42 (p = 0.16)
C
TNF antagonist – naive subgroup
Study or subgroup     Vedolizumab         Placebo Weight (%) Risk ratio Risk ratio
 Events Total Events Total  MH, fixed, 95% CI MH, fixed, 95% CI
Sandborn et al. 2013 41 112 13 77 71.8 2.17 (1.25–3.77)
Sands et al. 2014 16 51 6 50 28.2 2.61 (1.11–6.14)
Total (95% CI)  163  127 100.0 2.29 (1.44–3.65)
Total events 57  19
Heterogeneity: c2 = 0.13, df = 1 (p = 0.72); I2 = 0%
Test for overall effect: Z = 3.51 (p = 0.0004)
 0.01 0.1 1 10 100
 Favours [experimental]  Favours [control]
 0.01 0.1 1 10 100
 Favours [experimental]  Favours [control]
 0.01 0.1 1 10 100
 Favours [experimental]  Favours [control]
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were pooled. Results of the meta-analysis showed 
that clinical remission was significantly higher for 
patients who received vedolizumab as compared 
to control patients (Figure 4 A). The meta-analysis 
in subpopulations of patients revealed that clinical 
response was significantly higher for patients who 
received vedolizumab as compared to control pa-
tients in both subgroups: patients with previous 
failure of TNF antagonist treatment (Figure 4 B) 
and patients naive to earlier TNF antagonist treat-
ment (Figure 4 C).
Adverse events
A  summary of general adverse events (AEs) 
and serious adverse events (SAEs) is shown in Ta- 
ble III. Fewer patients treated with vedolizumab 
discontinued therapy due to AEs than those re-
ceiving placebo in the induction phase. The risk 
of discontinuation of the intervention due to 
SAEs was comparable between vedolizumab and 
control groups. Moreover, there were no differ-
ences between vedolizumab and placebo related 
to the risk of drug-related AEs and drug-related 
SAEs (Table III). 
A  statistical analysis was performed for AEs, 
SAEs and serious infections occurring during the 
induction phase of treatment of CD with vedoli-
zumab compared with placebo. In the intervention 
groups, the frequency of any AEs was similar to the 
control groups (Figure 5). There was no evidence 
of significant heterogeneity when data from the 
studies were pooled; therefore a fixed-effect mod-
el was used for analysis of the AEs. The meta-anal-
ysis revealed that risk of AEs was not significantly 
different for patients who received vedolizumab 
as compared with control patients (Figure 5 A). In 
the case of SAEs and serious infections, the results 
of the meta-analysis showed no significant differ-
ences between the groups (Figures 5 B and C).
Discussion
Crohn’s disease is difficult to treat, and a large 
percentage of patients with active Crohn’s disease 
do not have a response to available treatments at 
all or have an initial response that is not sustained 
[13–16]. 
Although natalizumab, a humanized monoclo-
nal antibody that inhibits α4 integrin, is effective 
Figure 4. Forest plot of meta-analysis for vedolizumab vs. placebo of response to treatment A) in the general popu-
lation (ITT analysis) at week 6, B) in the subpopulation of patients who reported no response and/or poor tolerance 
of the prior treatment with TNF antagonists at week 6, and C) in the TNF antagonist-naive subgroup at week 6
A
General population (ITT analysis)
Study or subgroup     Vedolizumab         Placebo Weight (%) Risk ratio Risk ratio
 Events Total Events Total  MH, fixed, 95% CI MH, fixed, 95% CI
Sandborn et al. 2013 69 220 38 148 49.0 1.22 (0.87–1.71)
Sands et al. 2014 82 209 47 207 51.0 1.73 (1.28–2.34)
Total (95% CI)  429  355 100.0 1.48 (1.18–1.85)
Total events 151  85
Heterogeneity: c2 = 2.25, df = 1 (p = 0.13); I2 = 56%
Test for overall effect: Z = 3.42 (p = 0.0006)
B
Subpopulation of patients who reported no response and/or poor tolerance of the prior treatment with TNF anatagonists
Study or subgroup     Vedolizumab         Placebo Weight (%) Risk ratio Risk ratio
 Events Total Events Total  MH, fixed, 95% CI MH, fixed, 95% CI
Sandborn et al. 2013 25 105 16 70 35.4 1.04 (0.60–1.81)
Sands et al. 2014 62 158 35 157 64.6 1.76 (1.24–2.50)
Total (95% CI)  263  227 100.0 1.51 (1.12–2.02)
Total events 87  51
Heterogeneity: c2 = 2.49, df = 1 (p = 0.11); I2 = 60%
Test for overall effect: Z = 2.73 (p = 0.006)
C
TNF antagonist – naive subgroup
Study or subgroup     Vedolizumab         Placebo Weight (%) Risk ratio Risk ratio
 Events Total Events Total  MH, fixed, 95% CI MH, fixed, 95% CI
Sandborn et al. 2013 87 112 44 77 81.1 1.36 (1.09–1.69)
Sands et al. 2014 20 51 12 50 18.9 1.63 (0.90–2.98)
Total (95% CI)  163  127 100.0 1.41 (1.14–1.74)
Total events 107  56
Heterogeneity: c2 = 0.34, df = 1 (p = 0.56); I2 = 0%
Test for overall effect: Z = 3.19 (p = 0.001)
 0.01 0.1 1 10 100
 Favours [experimental]  Favours [control]
 0.01 0.1 1 10 100
 Favours [experimental]  Favours [control]
 0.01 0.1 1 10 100
 Favours [experimental]  Favours [control]
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Table III. Summary of safety profile
End point Reference Vedolizumab 
n/N (%), N
Placebo
n (%), N
Any adverse event Sandborn et al. 2013 124/220 (56.0) 88/148 (59.0)
Sands et al. 2014 117/209 (56.0) 124/207 (60.0)
Drug-related adverse event Sandborn et al. 2013 ND ND
Sands et al. 2014 34/209 (16.0) 34/207 (16.0)
Discontinued because of adverse events Sandborn et al. 2013 ND ND
Sands et al. 2014 4/209 (2.0) 8/207 (4.0)
Serious adverse events: Sandborn et al. 2013 20/220 (9.0) 9/148 (6.0)
Sands et al. 2014 13/209 (6.0) 16/207 (8.0)
Drug-related serious adverse event Sandborn et al. 2013 ND ND
Sands et al. 2014 1/209 (< 1.0) 1/207 (< 1.0)
Discontinued because of serious adverse events Sandborn et al. 2013 ND ND
Sands et al. 2014 4/209 (2.0) 5/207 (2.0)
Serious infection Sandborn et al. 2013 1/220 (< 1.0) 2/148 (1.0)
Sands et al. 2014 2/209 (< 1.0) 0/207 (0.0)
ND – no data.
Figure 5. Forest plot of meta-analysis of adverse events for vedolizumab vs. placebo: A – any adverse event,  
B – serious adverse events, C – serious infection (ITT analysis)
A
Any adverse event
Study or subgroup     Vedolizumab         Placebo Weight (%) Risk ratio Risk ratio
 Events Total Events Total  MH, fixed, 95% CI MH, fixed, 95% CI
Sandborn et al. 2013 124 220 88 148 45.8 0.95 (0.79–1.13)
Sands et al. 2014 117 209 124 207 54.2 0.93 (0.79–1.10)
Total (95% CI)  429  355 100.0 0.94 (0.83–1.06)
Total events 241  212
Heterogeneity: c2 = 0.01, df = 1 (p = 0.91); I2 = 0%
Test for overall effect: Z = 1.00 (p = 0.32)
B
Serious adverse events
Study or subgroup     Vedolizumab         Placebo Weight (%) Risk ratio Risk ratio
 Events Total Events Total  MH, fixed, 95% CI MH, fixed, 95% CI
Sandborn et al. 2013 20 220 9 148 40.1 1.49 (0.70–3.19)
Sands et al. 2014 13 209 16 207 59.9 0.80 (0.40–1.63)
Total (95% CI)  429  355 100.0 1.08 (0.65–1.80)
Total events 33  25
Heterogeneity: c2 = 1.37, df = 1 (p = 0.24); I2 = 27%
Test for overall effect: Z = 0.30 (p = 0.76)
C
Serious infection
Study or subgroup     Vedolizumab         Placebo Weight (%) Risk ratio Risk ratio
 Events Total Events Total  MH, fixed, 95% CI MH, fixed, 95% CI
Sandborn et al. 2013 1 220 2 148 82.6 0.34 (0.03–3.68)
Sands et al. 2014 2 209 0 207 17.4 4.95 (0.24–102.53)
Total (95% CI)  429  355 100.0 1.14 (0.24–5.29)
Total events 3  2
Heterogeneity: c2 = 1.90, df = 1 (p = 0.17); I2 = 47%
Test for overall effect: Z = 0.16 (p = 0.87)
 0.01 0.1 1 10 100
 Favours [experimental]  Favours [control]
 0.01 0.1 1 10 100
 Favours [experimental]  Favours [control]
 0.01 0.1 1 10 100
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in inducing remission in patients with CD [17, 18], 
it is used rarely [17–19] because of the risk of pro-
gressive multifocal leukoencephalopathy (PML) 
[20]. Vedolizumab is gut-specific [21, 22], and no 
cases of PML have been reported with its use [23], 
so it is one of the potential benefits in the safety 
profile over natalizumab in CD treatment.
The results of this systematic review and meta- 
analysis including two RCTs [10, 11] showed that 
the clinical response and remission were signifi-
cantly higher for patients with CD treated with 
vedolizumab as compared to control patients, 
except for the subgroup of patients with previous 
TNF antagonist failure, for which no significant 
differences in clinical remission were revealed. 
Moreover, AEs, SAEs or serious infections were not 
more common in vedolizumab-treated patients 
than control patients. 
Importantly, our study is the first to focus not 
only on use of vedolizumab in the general CD pa-
tient population but also in suitable subgroups of 
patients. The results of our study suggested that 
although vedolizumab can be an accurate thera-
peutic approach for CD patients, the best clinical 
effect will be observed for patients naive to previ-
ous TNF antagonist treatment, and unfortunately 
for patients with anti-TNF failure the results will 
not be so unequivocal. That fact may be a key in 
the future therapeutic approach of CD treatment.
Generally, the results of this study demonstrat-
ed the superiority of vedolizumab over placebo in 
patients with CD. Our analysis supports the use of 
vedolizumab for the treatment of CD. 
It should be mentioned that the study by Fea-
gan et al. [12] – which we excluded from the me-
ta-analysis – was included in the meta-analysis 
by Wang et al. with the same two RCTs that were 
included by us [24]. The main reasons why we ex-
cluded the Feagan et al. study were the small num-
ber of study participants, the narrow age range of 
patients (23–52 years) and, what is the most im-
portant, the follow-up period and drug dosing reg-
imen being completely inconsistent with the other 
two RCTs (administration of vedolizumab due to 
summary of product characteristics was applied 
only in studies 10-11; Table II); our meta-analysis 
revealed results of the therapy according to the 
authorized dosage and therapy regimen, unlike 
that of Wang et al. Heterogeneity in dosage and 
regimen between trials makes the results of the 
meta-analysis more biased and less relevant to 
therapy used in real everyday clinical practice.
Moreover, as has been mentioned before, the 
difference between the Wang et al. study of 2014 
[24] and our study is that the former does not 
contain separate meta-analyses for efficacy of 
vedolizumab in subgroups of patients previously 
treated or untreated with TNF antagonists. This 
issue appears to be very important despite the 
fact that there is a significant difference between 
vedolizumab and placebo groups in clinical remis-
sion level for the general population of patients 
(RB = 1.77; 95% CI: 1.21–2.59; p = 0.003); there 
is no statistically significant difference in clinical 
remission for patients who previously reported no 
response and/or poor tolerance of the treatment 
with TNF antagonists (Figure 2). Aggregated re-
sults for clinical remission for the overall popu-
lation were similar when comparing Wang et al. 
and our results (RR = 1.71 vs. 1.77, respectively), 
and we confirmed the conclusion of a significant 
difference between vedolizumab and placebo for 
the endpoint.
This systematic review and meta-analysis in-
cludes both limitations and strengths. The prima-
ry limitation is the fact that only two RCTs were 
available for inclusion. The calculations in the me-
ta-analysis were based on published study results 
instead of individual patient data, which may gen-
erate bias. The included studies differed from each 
other in terms of the follow-up periods – but only 
results for the induction phase (6 weeks of treat-
ment in both clinical trials) were aggregated and 
analyzed in our study. Another important limitation 
of this review is the length of the follow-up period 
in the case of safety profile (6 weeks), which was 
not long enough to evaluate all possible adverse 
events of therapy; further studies on this issue 
should be performed for a longer follow-up.
The strengths of this systematic review and 
meta-analysis include strict methodology based 
on the methods and recommendations from the 
PRISMA Statement [7] concerning a  clear search 
strategy and predefined inclusion criteria for stud-
ies for the systematic review and meta-analysis. 
Data extraction and calculations were conducted 
independently by two authors. Furthermore, only 
RCTs were taken into consideration in this paper. 
The analyses were performed on the basis of ITT 
data, and depending on the heterogeneity of data, 
an appropriate statistical model was applied (fixed 
or random). Clinical outcomes were assessed using 
exactly the same definitions in both studies. Other 
important strengths of this meta-analysis concern 
the large number of patients included in the trials, 
and also the high quality of the eligible studies. 
Despite the above-mentioned limitations, this 
systematic review and meta-analysis made it pos-
sible to compare the effectiveness of vedolizumab 
with placebo in patients with CD.
In conclusion, the results of this systematic re-
view and meta-analysis demonstrated that vedol-
izumab therapy has a beneficial effect in the treat-
ment of CD, when compared with placebo. Based 
on the safety analysis, there was no evidence for 
an increase in the incidence of any adverse events. 
This analysis supports the use of vedolizumab for 
the treatment of CD. 
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